J&J Report Strong Second Quarter Results
Johnson & Johnson have reported strong results for their second quarter of 2013, with an 8.5% increase in sales. The increase was aided by robust results from their prostate cancer drug, Zytiga.
Net income reached $3.83 billion, a major increase from the $1.41 billion from the previous year’s quarter 2 period, aided by the gain on the sale of their stake in Ireland’s Elan Cor. Turnover was $17.88 billion, while worldwide pharmaceutical sales increased by 11.7% to $7.03 billion.
Johnson & Johnson’s largest seller was the Merck & Co-partnered anti-inflammatory Remicade (infliximab), sales of which were up 9.8% to $1.67 billion, while the latter’s follow-up Simponi (golimumab) soared up 40.0% to $175 million.
The most outstanding performance came from Zytiga (abiraterone), which contributed $395 million, an increase of 70.3%, while sales of Velcade (bortezomib) for multiple myeloma rose 19.2% to $379 million. Stelara (ustekinumab) for moderate to severe plaque psoriasis climbed 49.6% to $371 million. The HIV therapy Prezista (darunavir) also rose 16.6% to $435 million.
“At the mid-year point, we have achieved strong growth across our enterprise,” commented Johnson and Johnson’s chief executive, Alex Gorsky.
He added that the gains were made as a result of the progress in “restoring a reliable supply of OTC products to consumers, continuing the successful integration of Synthes and building on the strong momentum in our pharmaceutical business.”